Abstract Library

#1866 NET – Incidental Findings: Small, Silent and Innocent?

Introduction: Neuroendocrine tumours (NETs) are rare neoplasms, with an overall incidence of 2 cases per 100,000 individuals per year. This number is increasing due to improved diagnosis, classification and higher imaging sensitivity, which lead to discovering of small and clinically insignificant NETs.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Roque R

Authors: Peralta Ferreira M, Strecht J, Alberto Teixeira J, Glória L, Roque R,

Keywords: NET, incidentaloma,

#1195 Neuroendocrine Gene Transcript Analysis of Blood Identifies Stable or Progressive NET Disease Treated with Somatostatin Analogs.

Introduction: An issue in NET management is defining stable or progressive disease and effective treatment. An alternative to RECIST criteria is a sensitive, reproducible blood biomarker test. Somatostatin analogs (SSA) are a chief therapy but efficacy is subjective and based on symptom control and imaging.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Alaimo D, Callahan S, Lepensky C, Jonzzon S, Teixeira N,

Keywords: Biomarker, SSA,